Stages

During or after testing for systolic heart failure, your healthcare professional may tell you the stage of disease. Staging helps determine the most appropriate treatment. There are two main ways to determine the stage of heart failure:

New York Heart Association (NYHA) classification

This system groups heart failure into four categories by number. You may see Roman numerals used for these category names.

  • Class 1 heart failure. There are no heart failure symptoms during daily activities or mild exercise.
  • Class 2 heart failure. Everyday activities can be done without difficulty. But exertion causes shortness of breath or fatigue.
  • Class 3 heart failure. It's difficult to complete everyday activities.
  • Class 4 heart failure. Shortness of breath occurs even at rest. This category includes the most severe heart failure.

American College of Cardiology/American Heart Association classification

This stage-based classification system uses letters A to D. It includes a category for people who are at risk of developing heart failure.

  • Stage A. There are several risk factors for heart failure but no signs or symptoms.
  • Stage B. There is heart disease but no signs or symptoms of heart failure.
  • Stage C. There is heart disease and signs or symptoms of heart failure.
  • Stage D. There is advanced heart failure that needs specialized treatments.

Healthcare professionals often use the classification systems together to help decide the most appropriate treatment options. Your health professional can help you interpret your stage.

Sept. 26, 2026
  1. Self-check plan for HF management. American Heart Association. https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure/managing-heart-failure-symptoms. Accessed Sept. 1, 2026.
  2. HF and your ejection fraction explained. American Heart Association. https://www.heart.org/en/health-topics/heart-failure/heart-failure-tools-resources. Accessed Sept. 1, 2026.
  3. Walsh MN, et al. AHA/ACC/ESC/WHF expert consensus document: Second universal definition of heart failure (2026). Circulation. 2026; doi:10.1161/CIR.0000000000001455.
  4. Heidenreich PA, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; doi:10.1161/CIR.0000000000001063.
  5. Lala A, et al. The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and The American Society for Preventive Cardiology. Journal of Cardiac Failure. 2026; doi:10.1016/j.cardfail.2025.06.013.
  6. Heart failure and sex. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-failure/expert-answers/heart-failure-and-sex/faq-20433732. Accessed Sept. 1, 2026.
  7. Lichtenstein AH, et al. 2026 dietary guidance to improve cardiovascular health: A scientific statement from the American Heart Association. Circulation. 2026; doi:10.1161/CIR.0000000000001435.
  8. Piano MR, et al. Alcohol use and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2025; doi:10.1161/CIR.0000000000001341.
  9. Bonow RO, et al., eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed Sept. 1, 2026.
  10. Ferri FF. Heart failure. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Sept. 1, 2026.
  11. Acute heart failure (HF). Merck Manual Professional Version. https://www.merckmanuals.com/professional/cardiovascular-disorders/heart-failure/heart-failure-hf. Accessed Sept. 1, 2026.
  12. The dying patient. Merck Manual Professional Version. http://www.merckmanuals.com/professional/special-subjects/the-dying-patient/the-dying-patient. Accessed Sept. 1, 2026.
  13. Types of heart failure. American Heart Association. https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/types-of-heart-failure. Accessed Sept. 1, 2026.
  14. Maddox TM, et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2024; doi:10.1016/j.jacc.2023.12.024.
  15. Van Essen BJ, et al. Pharmacologic treatment of heart failure with reduced ejection fraction: An updated systematic review and network meta-analysis. Journal of the American College of Cardiology. 2025; doi:10.1016/j.jacc.2025.08.054.
  16. Butler J, et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): A double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet. 2025; doi:10.1016/S0140-6736(25)01665-4.
  17. Anker SD, et al. Intravenous ferric carboxymaltose in heart failure with iron deficiency: The FAIR-HF2 DZHK05 randomized clinical trial. JAMA. 2025; doi:10.1001/jama.2025.3833.
  18. Mentz RJ, et al. Ferric carboxymaltose in heart failure with iron deficiency. New England Journal of Medicine. 2023; doi:10.1056/NEJMoa2304968.
  19. What is a heart failure action plan? Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/heart-failure/expert-answers/heart-failure-action-plan/faq-20433731. Accessed Sept. 2, 2026.
  20. Gustafsson F, et al. Inotropic therapy in patients with advanced heart failure: A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2023; doi:10.1002/ejhf.2814.
  21. Levine GN, et al. Sexual activity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2012; doi:10.1161/CIR.0b013e3182447787.
  22. Overview of heart failure. Merck Manual Professional Version. https://www.merckmanuals.com/professional/cardiovascular-disorders/heart-failure/overview-of-heart-failure. Accessed Sept. 2, 2026.
  23. Life's Essential 8. American Heart Association. https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8. Accessed Sept. 1, 2026.
  24. NT-Pro B-type natriuretic peptide, serum. Mayo Clinic Laboratories. https://www.mayocliniclabs.com/test-catalog/overview/615897#clinical-and-interpretive. Accessed Aug. 5, 2026.
  25. Hollenberg SM, et al. 2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: A report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2024; doi:10.1016/j.jacc.2024.06.002.
  26. Russo AM, et al. ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 appropriate use criteria for implantable cardioverter-defibrillators, cardiac resynchronization therapy, and pacing. Journal of the American College of Cardiology. 2025; doi:10.1016/j.jacc.2024.11.023.
  27. Medical review (expert opinion). Mayo Clinic. Sept. 22, 2026.

Heart failure with reduced ejection fraction (HFrEF)